Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab in Anaplastic Thyroid Cancer
NCT04171622Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in anaplastic thyroid cancer (ATC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2021; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT04171622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171622.